The oLIVER project aims to identify new blood biomarkers to help diagnose and stage patients with the liver disease NAFLD. The current diagnosis relies on liver biopsies, which is both invasive and potentially dangerous, and therefore biomarkers from blood samples holds great potential for easier and safer diagnosis of liver disease. Novo Nordisk is industry partner in the oLIVER project.
On this page, you can find all of the news from ODIN, which is related to the oLIVER project. You are always welcome to contact Jørgen Kjems, if you would like more information about the oLIVER project.
oLIVER is short for "Identifying biomarkers for diagnosis and treatment evaluation of Non-Alcoholic Fatty Liver Disease (NAFLD)"
In ODIN, all findings and results will be shared openly.
Researchers working on ODIN projects are encouraged to upload all of their findings to the ODIN community on Zenodo - see the link to the right.
If you have any questions, you are more than welcome to contact the ODIN secretariat.